<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01164085</url>
  </required_header>
  <id_info>
    <org_study_id>091196</org_study_id>
    <nct_id>NCT01164085</nct_id>
  </id_info>
  <brief_title>Intravitreal Ketorolac for Chronic Uveitis: A Investigational Safety Study</brief_title>
  <acronym>INCITE</acronym>
  <official_title>Intravitreal Ketorolac for Chronic Uveitis:A Phase I Investigational Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intraocular delivery of ketorolac will be an effective means to treat inflammation and
      macular edema and prevent structural complications and vision loss in patients with uveitis
      who are unable to tolerate corticosteroids due to their side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I safety study of intravitreal ketorolac in patients with chronic inflammation and
      complications due to inflammation who have either failed medical therapy or who cannot
      tolerate corticosteroids due to side effects.

      Specific Aims

        1. Test the safety of intraocular injection of 4mg of ketorolac in patients who have
           intractable uveitis or complications of uveitis such as chronic macular edema who are
           unable to tolerate corticosteroids due to their side effects.

        2. Test the efficacy of intraocular 4m ketorolac of treating inflammation or structural
           complications of inflammation in patients with uveitis who are unable to tolerate
           corticosteroids due to their side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>90 days</time_frame>
    <description>Baseline and 90 day electroretinogram and goldmann visual fields will be compared to assess for retinal toxicity.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4mg intravitreal injection of ketorolac</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Ketorolac</intervention_name>
    <description>4mg of intravitreal ketorolac</description>
    <arm_group_label>Ketorolac</arm_group_label>
    <other_name>ketorolace, tromethamine, preservative free</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult volunteers

          -  Chronic intractable uveitis or chronic complications of uveitis (macular edema)despite
             maximal medical treatment

          -  Unable to tolerate corticosteroids due to side effects

        Exclusion Criteria:

          -  18 years or younger

          -  Have active ocular infection

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen J Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt Eye Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-8808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/22491916</url>
  </link>
  <results_reference>
    <citation>Kim SJ, Doherty TJ, Cherney EF. Intravitreal ketorolac for chronic uveitis and macular edema: a pilot study. Arch Ophthalmol. 2012 Apr;130(4):456-60. doi: 10.1001/archopthalmol.2011.2627. Erratum in: Arch Ophthalmol. 2012 Jun;130(6):742.</citation>
    <PMID>22491916</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2010</study_first_submitted>
  <study_first_submitted_qc>July 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2010</study_first_posted>
  <last_update_submitted>December 30, 2013</last_update_submitted>
  <last_update_submitted_qc>December 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Stephen J. Kim, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Macular Edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

